ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease

E Rijcken, C F Krieglstein, C Anthoni, M G Laukoetter, R Mennigen, H U Spiegel, N Senninger, C F Bennett, G Schuermann

Background: Recruitment of circulating cells to the inflamed intestine is modulated by adhesion molecules expressed on the surface of both leucocytes and endothelial cells.

Aims: The objective of this study was to test whether 2′-O-methoxyethyl chimeric antisense oligonucleotides directed against endothelial intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) can downregulate leucocyte-endothelial interactions and thereby attenuate inflammation in rat experimental ileitis.

Methods: Indomethacin (7.5 mg/kg) was injected subcutaneously into Sprague-Dawley rats 48 and 24 hours prior to intraovital microscopy. Animals were treated with either ICAM-1 (ISIS 17470), VCAM-1 (ISIS 18155), or scrambled control antisense oligonucleotides administered subcutaneously or intravenously in parallel with indomethacin. Leucocyte trafficking was observed in ileal submucosal collecting venules. Macroscopic and histological grades of inflammation were measured 48 hours after the first indomethacin application. ICAM-1 and VCAM-1 expression in ileal submucosal venules was detected by immunohistochemistry.

Results: Intravenous administration of ICAM-1 oligonucleotides 2 mg/kg (rolling leucocytes 5.7 (2.4)/0.01 mm² endothelial surface, adherent leucocytes 0.8 (1.1)) and VCAM-1 oligonucleotides 8 mg/kg (9.2 (4.4), 0.6 (0.8)) significantly reduced leucocyte adhesion compared with diseased controls (27.8 (5.3), 14 (4.4)) in a dose-dependent manner, whereas subcutaneous treatment did not. Correspondingly, macroscopic and histological inflammation was significantly decreased. ICAM-1 oligonucleotides markedly reduced endothelial ICAM-1 expression while VCAM-1 oligonucleotides clearly diminished endothelial VCAM-1 expression.

Conclusions: Both ICAM-1 and VCAM-1 2′-O-methoxyethyl chimeric antisense oligonucleotides attenuate rat ileitis by downregulation of leucocyte adherence and thus are potential candidates for anti-inflammatory treatment in inflammatory bowel disease.

In inflammatory bowel disease (IBD) there is a dense intestinal infiltrate of inflammatory cells which exhibit a distinct distribution for Crohn’s disease as well as ulcerative colitis. For the development of the local intestinal cellular infiltrate, circulating cells must adhere to the intestinal vascular endothelium and transmigrate into the tissue where the immuno-inflammatory reaction is created. A multistep cascade for adhesion of circulating leucocytes to endothelial cells has been proposed, involving specific families of adhesion molecules which are expressed on endothelial cells and leucocytes as ligands and counterparts. Interleukin (IL)-1α and IL-1β have been shown to block expression of specific targeted proteins by proinflammatory cytokines such as tumour necrosis factor (TNF)-α and interleukin (IL)-1α. Increased expression of endothelial ICAM-1 in inflamed tissues promotes the recruitment of inflammatory cells expressing its ligands leucocyte function antigen 1 (LFA-1) (CD11a/CD18) or MAC-1 (CD11b/CD18). Likewise, vascular cell adhesion molecule (VCAM)-1 belongs to the immunoglobulin superfamily and is expressed on activated endothelial cells, macrophages, dendritic cells, and fibroblasts. While binding to its ligands integrin α4β7 (very late antigen 4 [VLA-4]) and α4β1 on lymphocytes, monocytes, and eosinophils, VCAM-1 modulates leucocyte firm adhesion to endothelial cells and migration to sites of inflammation. Despite former assumptions, integrin α4 has also been shown to be expressed on the surface of neutrophils in rats, mice, and humans. There is increasing evidence that leucocytes can also directly tether, roll, and adhere to the endothelium under inflammatory conditions using the α4 integrin alone which may represent an alternative pathway to the established model of leucocyte adhesion. Upregulation of ICAM-1 has been shown in actively inflamed mucosa in IBD, mostly by means of immunohistochemistry, corresponding to elevated serum levels of both ICAM-1 and VCAM-1 in active disease. Only a few studies have failed to demonstrate increased ICAM-1 or VCAM-1 expression in human IBD tissue. However, in cell cultures and animal models ICAM-1 and VCAM-1 were markedly increased under inflammatory conditions. Therefore, reduction of ICAM-1 and VCAM-1 expression may elicit potent anti-inflammatory activity.

Synthetic phosphorothioate antisense oligonucleotides have been shown to block expression of specific targeted proteins by arrest of translation, inhibition of processing, or degradation of the targeted mRNA. Antisense oligonucleotides have been shown to block expression of specific targeted proteins by arrest of translation, inhibition of processing, or degradation of the targeted mRNA.

Abbreviations: FITC, fluorescein isothiocyanate; IBD, inflammatory bowel disease; ICAM-1, intercellular adhesion molecule 1; IL-1, interleukin 1; IVM, intravital microscopy; LFA-1, leucocyte function antigen 1; TNF-α, tumour necrosis factor α; VLA-1, very late antigen 1; VCAM-1, vascular cell adhesion molecule 1; PBS, phosphate buffered saline.
are oligomers, generally 15–25 bases in length, designed to bind to miRNA by complementary base pairing (hybridisation). Local and intravenous administration of antisense oligonucleotides against the p65 subunit of nuclear factor κB abrogated trinitrobenzene sulphonic acid induced colitis in mice. A murine specific ICAM-1 oligonucleotide (ISIS 3082) prevented dextran sulphate sodium induced colitis in mice in a dose dependent manner and a human specific ICAM-1 oligonucleotide (ISIS 2302) significantly lowered corticosteroid usage in a placebo controlled trial in patients with active steroid dependent Crohn’s disease. In this study, newly designed chimeric oligonucleotides containing modified sugar residues and deoxynucleotides were used. Phosphorothioate-oligonucleotides were modified by a methoxyethoxy group at the 2′ position of the ribose. These modifications exhibit an increase in potency, nuclease resistance, and duration of action compared with normal phosphorothioate oligonucleotides and lack immunostimulatory effects.

Using these modern oligonucleotides we investigated, by intravital microscopy (IVM), the effects of rat specific ICAM-1 (ISIS-17470) and VCAM-1 (ISIS 18155) second generation 2′-O-methoxymethyl chimeric oligonucleotides on leucocyte-endothelial interactions in a rat model of IBD. For the first time we have shown that intravenous administration of antisense oligonucleotides against VCAM-1 attenuates intestinal inflammation in an animal model of IBD. Furthermore, we demonstrated that intravenous application of ICAM-1 oligonucleotides was superior to subcutaneous application in controlling leucocyte endothelial adhesive interactions in this model of intestinal inflammation.

**METHODS**

**Induction of inflammation**

The experimental protocol was approved by the Animal Care Committee of the Regional Administration Muenster, Germany. Inbred male Sprague-Dawley rats (Charles River, Sulzfeld, Germany, 120–200 g) were single housed in standard laboratory cages with free access to water and food. Indomethacin (Sigma-Aldrich, Steinheim, Germany) at a dose of 7.5 mg/kg dissolved in 5% NaHCO3 (Merck, Darmstadt, Germany) was injected subcutaneously over the left lower abdominal quadrant 48 and 24 hours prior to IVM (fig 1). Stool samples were tested daily for occult blood using hemo-FEC (Boehringer Mannheim GmbH, Mannheim, Germany).

**Administration of oligonucleotides**

Oligonucleotides were obtained from ISIS Pharmaceuticals (Carlsbad, California, USA). ISIS 17470 is a rat specific 2′-O-methoxymethyl antisense oligonucleotide against ICAM-1 with the sequence 5’-TGTCAGGGTCAAGTGCATTAC-3’. The underlined section carries the 2′-O-methoxymethyl modification. ISIS 18155 (5’-CGGACGACTTACAGGGC-3’) is a 2′-O-1-methoxymethyl antisense oligonucleotide which specifically targets VCAM-1 in both rats and mice. As a scrambled control oligonucleotide, ISIS 18154 (5′-TCAGGCTGCCCAGGATCC-3’) was used. Parallel to subcutaneous indomethacin administration, oligonucleotides dissolved in phosphate buffered saline (PBS) were injected either subcutaneously or intravenously using a permanent central venous line (right jugular vein) 48 and 24 hours prior to IVM. A total of 110 rats were divided into 11 groups (each n=10). Four control groups received scrambled control oligonucleotides (ISIS 18154 2 or 8 mg/kg intravenously) and indomethacin, indomethacin alone (disease control), or the indomethacin carrier 5% NaHCO3, subcutaneously instead of indomethacin (healthy controls). Three treatment groups received indomethacin plus ICAM-1 oligonucleotides at 1 and 2 mg/kg subcutaneously, or at 2, 4, or 8 mg/kg intravenously. The initial dose of oligonucleotides, 1 mg/kg subcutaneously, was based on previous studies in a mouse model.

**Intravital microscopy**

Under ether inhalation narcosis (Chinonol, Seelze, Germany) polyethylene catheters (internal diameter 0.58 mm; Portex Ltd, Lythe, UK) were inserted into the right jugular vein and right carotid artery for administration of erythrocytes, contrast dyes, and pharmaceuticals as well as for monitoring arterial blood pressure and heart rate (Servomed, Hellige, Germany). Homologous erythrocytes were stained in vitro with fluorescein isothiocyanate (FITC; Sigma-Aldrich) before intravenous injection. Leucocytes were stained in vivo by intravenous injection of 17.5 µg/100 g rhodamine 6G (Sigma-Aldrich) immediately before IVM. Spontaneously breathing animals were placed in a supine position on a heating pad (37°C) providing constant body temperature. The abdomen was opened by midline laparotomy and an ileum segment was gently positioned on an adjustable microscope table. The exposed bowel was permanently superfused with 37°C warm saline and covered by cuprophane foil to avoid drying. Using an epiluminescence technique, leucocyte-endothelial cell interaction was visualised in 10 randomly selected ileal submucosal collecting venules (diameter 80–120 µm) after 15 minutes of equilibration, as previously described. A Zeiss fluorescence microscope was used, applying filters 450–490/515–565 nm for FITC and 510–560/>590 nm for rhodamine 6G, respectively. Final magnification ×760 on videoscreen was achieved by 16×0.5 mm water immersion objective (Plan-Neofluar, Zeiss, Germany) and a mounted videocamera using 0.5 zoom (FK 6990-IQ, Pieper, Germany). Microscopic images were recorded for offline quantitative assessment of microcirculatory parameters using a computer assisted analysis system (analySIS; Soft Imaging System GmbH, Muenster, Germany). In each vessel the mean value (D) of five venular diameters was calculated. Central line erythrocyte velocity (V) was determined by calculating the mean velocity of five single frame to frame tracked red blood cells. Flow rate (F) was calculated using the formula

\[ F = \frac{\pi \times (D/2)^2 \times V \times t}{10^6} \]

(=time). Leucocytes were defined as adherent when attached to the vessel wall for at least 30 seconds and as rolling when moving with a velocity less than 2/5 of that of erythrocytes at the centreline of the observed microvesSEL. Rolling and adherent cells were counted over a period of 30 seconds in a 100 µm section of the vessel and given as numbers per 0.01 mm² endothelial surface.

**Tissue analysis**

After IVM, animals were sacrificed by an overdose of potassium chloride injected into the right jugular vein. The
characterisation of leucocyte adhesion and inflammation in indomethacin induced ileitis. The macroscopic aspect of small bowel inflammation typical of indomethacin induced enteritis in rats was a discontinuous transmural inflammation with multiple ulcerations and erosions of the small bowel with hyperaemic and haemorrhagic lesions. Administration of indomethacin caused a 5.3-fold increase in leucocyte rolling (27.8 (5.3) v 2.5 (2.5) mm/s; p < 0.005) (fig 2) and a 68-fold increase in leucocyte adhesion (14.0 (4.4) v 0.2 (0.2) mm²; p < 0.005) (fig 3) compared with healthy controls. Macroscopic assessment of inflammation correlated closely with leucocyte rolling and also with leucocyte adherence (rolling leucocytes r = 0.73, p < 0.05; adherent leucocytes r = 0.82, p < 0.05). Scrambled control oligonucleotides (ISIS 18155) 2 mg/kg intravenously did not reduce leucocyte rolling or adherence (24.9 (9.6)/0.01 mm² and 15.5 (4.5)/0.01 mm², respectively; NS v indomethacin). Increasing the dose of scrambled control oligonucleotides up to 8 mg/kg intravenously also did not influence leucocyte adhesion (25.2 (6.1)/0.01 mm² and 17.5 (4.0)/0.01 mm², respectively; NS v indomethacin or scrambled control 2 mg/kg intravenously). The oligonucleotide carrier PBS did not influence leucocyte-endothelial interactions. Scrambled control oligonucleotides 2 mg/kg intravenously showed the full macroscopic (4.2 (0.8) points (scrambled control) v 4.5 (0.7) (indomethacin)) and histological (5.1 (2) v 5.7 (2.4); NS) picture of indomethacin induced rat ileitis. This was confirmed by the higher dose of scrambled control oligonucleotides at 8 mg/kg intravenously (macroscopic 4.5 (0.7) points and histological 6 (1.8) points). As in the indomethacin group, occult faecal blood testing in all scrambled control oligonucleotide treated animals was 100% positive 48 hours after the first application of indomethacin. Erythrocyte velocity (mean 2250.8 (228.1) µm/s), blood flow (mean 1.1 (0.2) µl/min), and venular diameter (mean 101.0 (7.5) µm) were not significantly different between the groups. Haematological investigations of peripheral blood showed 32.5% neutrophils, 63.2% lymphocytes, 2.1% monocytes, and 1.4% eosinophils at 48 hours after the first application of indomethacin.
Intercellular adhesion molecule 1 (ICAM-1) expression in rat submucosal venules detected by immunohistochemistry using the peroxidase technique 48 hours after the first application of indomethacin (Indo). Two intravenous (iv) or subcutaneous (sc) doses of 2 mg/kg intercellular adhesion molecule 1 (ICAM-1) antisense oligonucleotides and two iv doses of both 4 mg/kg and 8 mg/kg vascular cell adhesion molecule 1 (VCAM-1) antisense oligonucleotides significantly reduced macroscopic intestinal inflammation. Values are mean (SEM) (n=10). SC, scrambled control oligonucleotides.

**Figure 4** Macroscopic inflammation 48 hours after the first application of indomethacin (Indo). Two intravenous (iv) or not subcutaneous (sc) doses of 2 mg/kg intercellular adhesion molecule 1 (ICAM-1) antisense oligonucleotides and two iv doses of both 4 mg/kg and 8 mg/kg vascular cell adhesion molecule 1 (VCAM-1) antisense oligonucleotides significantly reduced macroscopic intestinal inflammation. Values are mean (SEM) (n=10). SC, scrambled control oligonucleotides.

**Figure 5** Histological inflammation 48 hours after the first application of indomethacin (Indo). Two intravenous (iv) or not subcutaneous (sc) doses of 2 mg/kg intercellular adhesion molecule 1 (ICAM-1) antisense oligonucleotides and two iv doses of 8 mg/kg vascular cell adhesion molecule 1 (VCAM-1) antisense oligonucleotides significantly diminished histological intestinal inflammation. Values are mean (SEM) (n=10). SC, scrambled control oligonucleotides.

**Effect of ICAM-1 antisense oligonucleotides in intestinal inflammation**

Intravenous administration of ICAM-1 oligonucleotides at a dose of 2 mg/kg 48 and 24 hours prior to IVM caused a significant decrease in both leucocyte rolling (5.7 (2.4) v 27.8 (5.3)/0.01 mm²; p<0.05) and adherence (0.8 (1.1) v 14.0 (4.4)/0.01 mm²; p<0.05) compared with inflamed controls (figs 2, 3). Injection of ICAM-1 oligonucleotides at 1 mg/kg or 2 mg/kg subcutaneously 48 and 24 hours prior to IVM failed to show a significant effect on leucocyte adhesion or on macroscopic or histological inflammation, although a tendency towards blunting cell adhesion was observed (figs 2–5). Macroscopic (0.6 (1.1) v 4.5 (0.7) points) (fig 4) and histological (0.6 (0.8) v 5.7 (2.4) points; p<0.001) (fig 5) appearance of inflammation was significantly decreased by intravenous administration of ICAM-1 oligonucleotides 2 mg/kg, and the appearance of occult faecal blood at the time of IVM was reduced to 30%. In terms of macroscopic and histological inflammation, the effects of ICAM-1 oligonucleotides at 2 mg/kg were significantly dependent on the route of administration, as intravenous and subcutaneous administration differed significantly (p=0.035). Immunohistochemically, little constitutive ICAM-1 expression was detected in submucosal venules in healthy animals. Strong staining of ICAM-1 in submucosal venules in animals with indomethacin induced ileitis indicated that ICAM-1 expression was clearly upregulated compared with healthy controls. In animals treated with indomethacin and ICAM-1 oligonucleotides at a dose of 2 mg/kg intravenously, staining of ICAM-1 in submucosal venules was markedly reduced compared with diseased controls (fig 6).

**Effect of VCAM-1 antisense oligonucleotides in intestinal inflammation**

VCAM-1 oligonucleotides at a dose of 8 mg/kg administered intravenously reduced both rolling (9.2 (4.4)/0.01 mm²; p<0.05) and adherent (0.6 (0.8)/0.01 mm²; p<0.05) leucocytes significantly (figs 2, 3). Treatment with VCAM-1 oligonucleotides 8 mg/kg intravenously significantly reduced
macroscopic (0.5 (1.1); p<0.001) (fig 4) and histological (0.7 (1.5); p=0.002) inflammation (fig 5). Occult faecal blood was found at the time of IVM in 20% of animals treated with VCAM-1 oligonucleotides 8 mg/kg intravenously. Also, VCAM-1 oligonucleotides 4 mg/kg intravenous attenuated indomethacin induced inflammation macroscopically (p=0.001), although at this dose reduction of rolling and adherent leukocytes or histological inflammation was apparent but not significantly different. Immunohistochemically, VCAM-1 expression 48 hours after the first application of indomethacin was strong in diseased animals but rare in healthy controls. VCAM-1 was barely detectable in submucosal and mesenteric venules in animals treated with VCAM-1 oligonucleotides dosed at 8 mg/kg intravenously (fig 7).

DISCUSSION
Since the understanding of the development of the intestinal cellular infiltrate has improved, prevention of cellular sequestration into intestinal tissues by blockade of adhesion molecules has become a major goal for therapeutic and prophylactic interventions. The use of oligonucleotides interfering with translation of mRNA of cell adhesion molecules seems promising to achieve this. Both 2′-O-methoxymethyl chimeric phosphorothioate antisense oligonucleotides (ISIS 17470 and ISIS 18155) designed to selectively inhibit ICAM-1 and VCAM-1 expression in rat cells reduced leucocyte-endothelial interactions and prevented the development of indomethacin induced ileitis in a dose dependent manner, suggesting both adhesion molecules play a central role in the recruitment of leukocytes in this model.

The indomethacin model of acute intestinal inflammation is mainly driven by infiltrating neutrophils. This is well documented in morphological and immunohistochemical studies as well as in measurements of myeloperoxidase levels, which reflect neutrophil content in the tissue. Although the pathogenesis of indomethacin induced intestinal inflammation remains unclear, increased mucosal permeability, bacterial translocation, microvascular disturbances, cyclooxygenase inhibition, and enterohepatic circulation of indomethacin seem to play important roles in the initiation of the disease. At advanced stages of inflammation, macrophages and lymphocytes are also present at sites of inflammation. Eosinophils or basophils have not been investigated in this model so far. Using immunohistochemical staining, we found marked enhancement of endothelial ICAM-1 and VCAM-1 expression in ileal submucosal and mesenteric venules in indomethacin induced ileitis compared with healthy controls. In a previous study using the dual labelled antibody method, we found clear upregulation of intestinal ICAM-1 expression during the first 30 hours of inflammation but at later stages ICAM-1 seemed to be reduced. This could not be reproduced in our immunohistochemical studies in which ICAM-1 was still increased after 48 hours. However, expression of both adhesion molecules was clearly reduced after treatment with VCAM-1 or ICAM-1 oligonucleotides, indicating that amelioration of inflammation was mediated by inhibition of cell adhesion molecule transcription. A non-antisense mediated biological activity could be excluded by showing that scrambled control treated animals at both doses, and animals in the indomethacin group, were equally diseased. Therefore, it seems reasonable that infiltrating neutrophils adhere to the endothelium via both ICAM-1 and VCAM-1 in this model.

The β2 integrins LFA-1 and MAC-1 are expressed on the surface of neutrophils, monocytes, and natural killer cells. Lymphocytes however seem to express primarily LFA-1, enabling these inflammatory cells to bind to endothelial ICAM-1 and transmigrate into the tissue. Blockade of ICAM-1 by monoclonal antibodies or antisense oligonucleotides reduces intestinal inflammation in various models. The ligand of VCAM-1, VLA-4, is expressed on lymphocytes but is also expressed on neutrophils under certain conditions. Interestingly, in a state of inflammation, the α4β1/VCAM-1 pathway of neutrophil recruitment seems to develop increasing importance. Our observation that inhibiting VCAM-1 expression by means of antisense oligonucleotides blocks neutrophil recruitment can be explained by these findings. With regard to prophylactic treatment in our model, inhibition of lymphocyte recruitment in the later stages of this model by VCAM-1 antisense oligonucleotides may be of minor importance. In other models of IBD with a more chronic character, monoclonal antibodies versus VCAM-1 were highly effective in the control of intestinal inflammation. VCAM-1 expression has been shown to be markedly upregulated in these models and was even well correlated with myeloperoxidase levels. The role of ICAM-1 and VCAM-1 in firm adherence of leucocytes to endothelial cells is well established but both adhesion molecules also support leucocyte rolling. IVM studies demonstrate that ICAM-1 is required for optimal P- and L-selectin mediated rolling of leucocytes in inflamed vessels while blockade of VCAM-1 results in increased rolling velocity of mononuclear cells. The observation that a certain antisense oligonucleotide at a high enough dose shows leucocyte adhesion comparable with that seen in healthy controls does not imply that rolling or sticking was completely abrogated. Rather it has been shown that ICAM-1 and
VCAM-1, respectively, were crucial for the development of intestinal inflammation in this model. The reduction in leucocyte adhesion may also have been a consequence of a general decrease in leucocyte and endothelial activation in oligonucleotide-treated animals. This might have been caused by interrupting the amplification of the inflammatory response, which is normally generated by chemotactic reagents such as IL-8 or MIP-1 released by transmigrated inflammatory cells. Apparently, both LFA-1/ICAM-1 and VLA-4/VCAM-1 interactions play a central role in this process. Reducing the adhesion cascade to a certain threshold may also disturb alternative pathways of leucocyte activation and recruitment in this model.

When comparing ICAM-1 and VCAM-1 oligonucleotides given at the same doses and by the same administration route, ICAM-1 might be more effective than VCAM-1. Nevertheless, it must be considered that in animal models VCAM-1 upregulation under inflammatory conditions is stronger than ICAM-1 and therefore VCAM-1 oligonucleotides had to be given at a four times higher dose to produce similar effects. This may be a consequence of the different epitope targeted but may also be due to the different structures of the oligonucleotides, underlying the need for specific testing of pharmacokinetics of each individual oligonucleotide before application. Future studies might examine the beneficial effects of a combination of ICAM-1 and VCAM-1 oligonucleotides in terms of dose reduction and additional decrease in inflammation. Macroscopic inflammation was significantly reduced by VCAM-1 oligonucleotides at a dose of 4 mg/kg intravenously although leucocyte adhesion and histological inflammation were not. This may be explained by previous studies showing altered expression of cell adhesion molecules in uninvolved gut; thus adhesion of circulating leucocytes to the mucosal endothelium may precede macroscopic visible inflammation. Influx of inflammatory cells into the tissue is a dynamic process which is constantly perpetuated during inflammation. Therefore, patients with established IBD may benefit from oligonucleotides against ICAM-1 or VCAM-1. As VCAM-1 expression is very rare in healthy subjects but strongly upregulated under inflammatory conditions, VCAM-1 seems to be a more specific drug target compared with ICAM-1 which is constitutively expressed and upregulated to a lower extent. However, VCAM-1 has not been shown to be upregulated in biopsy specimens from patients with IBD as plasma levels of sVCAM-1 were increased in these patients and monoclonal antibodies versus the α4 integrin showed promising effects in reduction of the disease activity index in patients with active Crohn’s disease, a VCAM-1/α4 interaction may also be important in human intestinal inflammation. Given recurrent cellular infiltration at the sites of surgical anastomoses in up to 50% of cases even three months after surgery, permanent local control of cellular sequestration with the help of intestinal oligonucleotides against ICAM-1 or VCAM-1 seems reasonable. To this aim, oligonucleotides seem to be preferable and humanised monoclonal antibodies (approximately 95% human) and humanised monoclonal antibodies (approximately 95% human). Further studies should aim to design pharmacological preparations which provide high levels of local intestinal oligonucleotides for long lasting suppression of cell adhesion and intestinal inflammation in IBD.

ACKNOWLEDGEMENTS
Supported by a research grant from the Crohn’s Disease and Ulcerative Colitis Foundation of Germany DCCV eV and a research grant from the Westphalian Wilhelms-University Muenster (IMF SC-1-1-I1 (96/3)). Dr CF Bennett is employed at ISIS Pharmaceuticals, Carlsbad, CA 92008, USA.

Authors’ affiliations
E Rijken, C F Kriegstein, C Anthoni, M G Loukoetter, R Mennigen, H Spiegel, N Senninger, G Schuermann, Department of General Surgery, Westphalian Wilhelms-University, Muenster, Germany
C F Bennett, ISIS Pharmaceuticals, Carlsbad, CA 92008, USA

†E Rijken and C F Kriegstein contributed equally to this work.

REFERENCES

Gut: first published as 10.1136/gut.51.4.529 on 1 October 2002. Downloaded from http://gut.bmj.com/ on August 5, 2023 by guest. Protected by copyright.